SCHEMBL5751385

SCHEMBL5751385

COc1ccc2cc(Br)ccc2c1CO

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.64
RXFP1 Q9HBX9 5/20 0.61
LMNA P02545 5/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
KDM4E B2RXH2 2/20 0.56
MAPT P10636 2/20 0.55
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 2/20 0.51
NCEH1 Q6PIU2 2/20 0.44
KDM2B Q8NHM5 2/20 0.44
EPHA2 P29317 1/20 0.43
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7817956 0.94 POLB (0.59) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL15414460 0.89 POLB (0.51) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL7812634 0.88 POLB (0.61) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL29262551 0.85 RXFP1 (0.63) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL5751823 0.84 POLB (0.60) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL3831940 0.84 POLB (0.60) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL806311 0.82 ACHE (0.46) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL24075355 0.82 POLB (0.46) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL15414055 0.81 KDM2B (0.44) POLBRXFP1LMNASMN1; SMN2L3MBTL1
SCHEMBL5752998 0.80 POLB (0.55) POLBRXFP1LMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221500-A Preparation method of chloro aromatic compound 大连理工大学 2024-06-21 CN disclosed
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) 2013-04-04 US disclosed
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) 2013-04-04 US disclosed
US-7084149-B2 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-08-01 US disclosed
EP-1073640-B1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL (JP) 2005-04-13 EP disclosed
US-20030236274-A1 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-25 US disclosed
US-6573289-B1 Naphthalene derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-06-03 US disclosed
EP-1073640-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-02-07 EP disclosed
WO-1999054309-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236274-A1 Naphthalene derivatives, their production and use CYP17A1, CYP21A2, HSD17B1 POLB 2225/4885RXFP1 3175/4885LMNA 3058/4885
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT MAVS, SNRPE, LONP1 POLB 864/4885RXFP1 2678/4885LMNA 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.